Familial atrial fibrillation is a genetically heterogeneous disorder  by Darbar, Dawood et al.
Atrial Fibrillation/Flutter, Tachycardia
Familial Atrial Fibrillation
Is a Genetically Heterogeneous Disorder
Dawood Darbar, MD,* Kathleen J. Herron, BA,* Jeffrey D. Ballew, MSC,* Arshad Jahangir, MD,*
Bernard J. Gersh, MBCHB, DPHIL, FACC,* Win-K. Shen, MD, FACC,*
Stephen C. Hammill, MD, FACC,* Douglas L. Packer, MD, FACC,* Timothy M. Olson, MD*†
Rochester, Minnesota
OBJECTIVES The aims of this study were to identify and characterize familial cases of atrial fibrillation (AF)
in our clinical practice and to determine whether AF is genetically heterogeneous.
BACKGROUND Atrial fibrillation is not generally regarded as a heritable disorder, yet a genetic locus for
familial AF was previously mapped to chromosome 10.
METHODS Of 2,610 patients seen in our arrhythmia clinic during an 18-month study period, 914 (35%)
were diagnosed with AF. Familial cases were identified by history and medical records review.
Four multi-generation families with autosomal dominant AF (FAF 1 to 4) were tested for
linkage to the chromosome 10 AF locus.
RESULTS Fifty probands (5% of all AF patients; 15% of lone AF patients) were identified with lone AF
(age 41  9 years) and a positive family history (1 to 9 additional relatives affected). In FAF
1 to 3, AF was associated with rapid ventricular response. In contrast, AF in FAF-4 was
associated with a slow ventricular response and, with progression of the disease, junctional
rhythm and cardiomyopathy. Genotyping of FAF 1 to 4 with deoxyribonucleic acid markers
spanning the chromosome 10q22-q24 region excluded linkage of AF to this locus. In FAF-4,
linkage was also excluded to the chromosome 3p22-p25 and lamin A/C loci associated with
familial AF, conduction system disease, and dilated cardiomyopathy.
CONCLUSIONS Familial AF is more common than previously recognized, highlighting the importance of
genetics in disease pathogenesis. In four families with AF, we have excluded linkage to
chromosome 10q22-q24, establishing that at least two disease genes are responsible for this
disorder. (J Am Coll Cardiol 2003;41:2185–92) © 2003 by the American College of
Cardiology Foundation
Atrial fibrillation (AF) is the most common sustained
arrhythmia in clinical practice, affecting more than two
million adults in the U.S. (1). The mean age of individuals
with AF is 75 years; disease prevalence increases with age
(2.3% age 40 years, 5.9% age 65 years) and with the
presence of structural heart disease. Atrial fibrillation results
in substantial morbidity, with the augmented risk of stroke
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being the most serious. In the elderly, the relative risk of
stroke in persons with non-rheumatic AF is 4.5 times that
of persons in sinus rhythm (2). Atrial fibrillation also
increases the risk of mortality; the age-adjusted odds ratio
for death with AF is 2.4 in men and 2.5 in women (3).
While death and stroke are clearly the most serious hazards,
AF can produce other complications including adverse
hemodynamics, congestive heart failure, and tachycardia-
induced cardiomyopathy. Thus, the morbidity and mortality
of AF are substantial, as are the socioeconomic conse-
quences of repeated hospital admissions, chronic disease
management, and disabilities.
The molecular determinants of AF are poorly under-
stood. In the elderly, AF is often associated with underlying
heart disease such as ischemic, hypertensive, myocardial, or
valvular disease. By contrast, idiopathic or “lone” AF typi-
cally occurs in young and middle-aged adults (mean age at
diagnosis  44 years) (4). The prevalence of lone AF,
depending on the age of the population under consider-
ation, ranges from 3% to 11% (4,5). Among patients with
lone AF, an unknown proportion have a familial form of the
disease with a genetic basis. Familial AF was first reported
in 1943 (6), but there has been no attempt to determine the
overall prevalence of familial disease. A recent report,
however, suggests that familial AF may be more common
than previously recognized (7).
Identification of a gene responsible for AF will provide
important insights into the etiology of familial disease. The
chromosomal location of an AF gene was first reported in
1997 based on genetic mapping studies in three families
from Spain who appeared to share common ancestry (8).
However, the gene responsible for AF in these families has
not yet been identified. Moreover, the overall importance of
this locus in other families with AF is unknown. In this
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study, we sought to identify and characterize familial cases
of AF and to determine whether or not AF is a genetically
heterogeneous disorder.
METHODS
Clinical evaluation. Between November 2000 and April
2002, patients referred to our Arrhythmia Clinic with lone
AF and a positive family history documented by the primary
physician, were identified. Family history data were avail-
able in the medical record in 90% of patients with AF. A
more detailed family history was subsequently obtained by a
study coordinator, following written informed consent un-
der a protocol approved by the Institutional Review Board
of the Mayo Clinic. When possible, first- and second-
degree relatives were contacted directly to obtain medical
records and review cardiac symptoms. Screening electrocar-
diography (ECG) and echocardiography was performed in
consenting members of four families (FAF 1 to 4), if these
tests had not been previously done for clinical indications.
Probands and their relatives were clinically classified
using a consistently applied set of definitions. Atrial fibril-
lation was defined as replacement of sinus P waves by rapid
oscillations or fibrillatory waves that varied in size, shape,
and timing and were associated with an irregular ventricular
response when atrioventricular conduction was intact. Doc-
umentation of AF on an ECG, rhythm strip, event monitor,
or Holter monitor recording was required. “Lone AF” was
defined as AF in individuals 60 years of age without
hypertension or overt structural heart disease by clinical
examination, ECG, and echocardiography (4). The upper
limits of normal for cardiac chamber dimensions were based
on age and body surface area (9). Relatives with AF
occurring at any age in the setting of structural heart disease
(hypertensive, ischemic, myocardial, or valvular) were clas-
sified as “uncertain” for having an inherited form of AF.
The “uncertain” classification was also used when documen-
tation of AF on an ECG tracing was lacking in relatives
with symptoms consistent with AF (palpitations, dyspnea,
light-headedness) or when a screening ECG and echocar-
diogram were not performed, regardless of symptoms.
Relatives were classified as “unaffected” if they were 18
years of age, asymptomatic, and had a normal ECG.
“Paroxysmal AF” was defined as AF lasting more than 30 s
that terminates spontaneously. The AF was classified as
“persistent” when it lasted more than seven days and
required either pharmacologic therapy or electrical cardio-
version for termination. Three classifications for familial AF
were used, based on increasingly stringent definitions: “pos-
sible” familial AF, one additional first- or second-degree
relative with lone AF by history alone (symptoms of AF
without known structural heart disease but without confir-
mation of lone AF in medical records); “probable” familial
AF, 2 additional first- or second-degree relatives with
lone AF by history alone, or one additional relative with
documented lone AF; “confirmed” familial AF, 2 addi-
tional first- or second-degree relatives with documented
lone AF.
Molecular genetic studies. Whole blood for genomic
deoxyribonucleic acid (DNA) extraction was obtained from
the index case and consenting family members. For geno-
typing, we selected eight polymorphic dinucleotide repeat
markers (10) spanning a previously reported locus for
familial AF on chromosome 10q22-q24 (8). The marker set
included the two flanking markers, D10S1694 and
D10S1786, which define boundaries of the 11 centiMorgan
(cM) AF locus; two markers that lie just distal to each of the
flanking markers, D10S1650 and D10S1717; and four
internal markers. The eight tightly linked markers (inter-
marker distances 1 to 3 cM) were amplified by the poly-
merase chain reaction (PCR) and resolved by polyacryl-
amide gel electrophoresis as previously described (11).
Genotypes were scored and used to construct haplotypes to
test for linkage. Family members phenotypically classified as
“unaffected” and “uncertain” were included in these analyses
to aid in construction of haplotypes. However, exclusion of
linkage was based on a stringent “affecteds-only” analysis
whereby lack of a shared chromosome segment among the
affected members of each family was required. Similarly,
markers were selected to test for linkage to two loci
previously associated with familial AF and dilated cardio-
myopathy. For the chromosome 3p22-p25 locus, the five
markers used in the original report were used (11). For the
lamin A/C gene on chromosome 1q21 (12), we identified
novel polymorphic markers. This was accomplished by a
“find text” search for potentially polymorphic repetitive
sequences in the genomic contig harboring lamin A/C
(NT_004858). Two dinucleotide repetitive sequences were
found: (TG)5(TA)8TG(CA)10, 5.1 kilobases 5 of the start
codon, and (GT)22, 2.4 kilobases 3 of the stop codon.
Oligonucleotide primer pairs were designed for PCR am-
plification by use of OLIGO 6.51 Primer Analysis Software
(National Biosciences, Plymouth, Minnesota).
RESULTS
Clinical evaluation. Of 2,610 patients referred to the
Arrhythmia Clinic during the 18-month study period, 914
(35%) had documented AF (mean age 68 15 years). Lone
AF was present in 325 (36%). Fifty probands (5% of all
Abbreviations and Acronyms
AF  atrial fibrillation
cM  centiMorgan
DNA  deoxyribonucleic acid
ECG  electrocardiogram/electrocardiographic/
electrocardiography
FAF  multi-generation families with autosomal
dominant atrial fibrillation
PCR  polymerase chain reaction
2186 Darbar et al. JACC Vol. 41, No. 12, 2003
Familial Atrial Fibrillation June 18, 2003:2185–92
Table 1. Phenotypic and Family Data for Patients With Familial Atrial Fibrillation
Gender
Age at
Evaluation
(yrs)
Age at
Onset
(yrs) Rhythm Treatment
HR
(beats/min) ECG
Echocardiography
Comment
Relatives
LA and
LV Size
EF
(%)
#
Affected
Age at Onset
(decade)
Possible familial AF
M 57 55 PersAF AAD, RFA 66 normal normal 65 1 5
M 60 42 PAF AAD, AVNA, PPM 40 normal normal 60 CVA 1 5
M 54 40 PAF AAD, RFA 64 normal LAE 40 2°CM 1 5
M 50 39 PAF AAD, RFA 75 normal BAE 65 1 4
M 46 42 PAF AAD, RFA 74 normal LAE 50 1 4
M 60 40 PAF AAD, RFA 72 normal LAE 65 1 4
M 43 30 PAF AAD, RFA 81 IVCD LAE 65 1 4
M 53 43 PAF AAD, RFA 78 normal LAE 60 1 5
M 57 44 PAF AAD, RFA 72 IVCD LAE 60 1 5
Probable familial AF
M 49 25 PAF AAD, RFA 109 normal BAE 65 2 5,6
M 57 50 PAF AAD, RFA 60 IVCD normal 61 1 4
M 46 41 PAF AAD, RFA 51 1°AVB BAE 60 3 4,5,5
F 57 40 PAF AAD, RFA 68 normal LAE 60 3 4,4,5
M 50 45 PersAF AAD, RFA 140 normal normal NA CVA 2 4,5
M 46 43 PAF AAD, RFA 71 1°AVB LAE 65 3 4,4,4
M 47 41 PAF AAD, RFA 75 IVCD LAE 60 3 4,4,4
M 35 31 PAF AAD, RFA 66 IVCD RAE 74 1 4
M 55 31 PersAF AAD, RFA 54 IVCD BAE 65 1 4
M 47 43 PAF AAD, RFA 61 normal LAE 60 2 4,4
M 53 49 PersAF AAD, AVNA, PPM 130 normal LAE,
LVE
37 2°CM 2 4,4
M 46 28 PAF AAD, RFA 74 1°AVB,
RBBB
LAE 65 3 4,4,5
M 59 54 CAF AAD, RFA 65 RBBB,
QTc
normal 37 2°CM 1 4
M 38 36 PAF AAD, AVNA, PPM 51 IVCD normal 65 2 4,5
M 54 25 PAF AAD, RFA 92 IVCD normal NA 2 4,5
M 50 38 CAF AAD, RFA 110 normal RAE,
LVE
29 2°CM 1 5
F 58 38 PAF AAD, RFA 54 normal normal 65 2 4,5
M 38 27 PAF AAD 74 normal BAE 55 2 3,4
M 52 48 CAF AAD 78 normal LAE 65 3 4,5,5
M 48 44 PAF AAD 68 normal normal 65 1 4
M 61 52 PAF AAD 114 normal normal 60 2 4,5
M 55 48 CAF AAD 97 normal normal 66 3 4,4,5
M 58 48 CAF AAD, RFA 82 QTc LAE 63 3 2,3,4
Confirmed familial
AF
M 59 54 PersAF AAD, RFA 61 IVCD RAE 40 2°CM 2 4,5
M 29 25 PAF AAD, RFA 74 IVCD normal 65 2 3,3
M 51 25 PAF AAD 57 1°AVB,
IVCD
normal 65 2 3,4
M 39 34 PAF AAD, RFA 88 normal normal 60 7 3,4,4,5,5,5,5
M 54 48 PAF AAD 78 1°AVB LAE 65 3 4,4,4
M 51 38 PAF AAD, RFA 66 1°AVB,
IVCD
normal 63 3 4,4,4
M 38 24 PersAF AAD 117 normal normal 60 2 4,5
M 65 45 CAF AAD, AVNA, PPM 40 LBBB LAE 68 4 4,4,5,5
F 52 37 PersAF AAD, RFA 74 IVCD LAE 65 4 4,4,4,4
F 54 44 PAF AAD, RFA 74 normal LAE 68 WPW in 2
relatives
4 3,3,4,4
M 55 49 PersAF AAD, ICD 55 normal LAE 60 4 4,4,4,4
M 62 50 CAF AAD 71 normal normal 65 3 4,4,4
F 41 39 PAF AAD, RFA 81 normal normal 65 2 3,4
M 57 40 CAF AAD, AVNA, PPM 70 normal BAE 65 3 3,3,4
AAD  antiarrhythmic drugs; AF  atrial fibrillation; 1°AVB  first-degree atrioventricular block (PR  0.20 s); AVNA  atrioventricular node ablation; BAE  biatrial
enlargement; CAF chronic atrial fibrillation; 2°CM secondary cardiomyopathy; CVA cerebrovascular accident; ECG electrocardiogram; EF ejection fraction; HR
heart rate (on drug therapy); ICD  implantable cardioverter defibrillator; IVCD  intraventricular conduction delay (QRS: 0.10 to 0.12 s); LA  left atrial; LAE  left atrial
enlargement; LBBB  left bundle-branch block, LV  left ventricular; LVE  LV enlargement; NA  not available; PAF  paroxysmal atrial fibrillation; PersAF  persistent
atrial fibrillation; PPM  permanent pacemaker; QTc  corrected QT interval 500 ms; RAE  right atrial enlargement; RBBB  right bundle-branch block; RFA 
radiofrequency ablation of focal atrial fibrillation; WPW  Wolff-Parkinson-White syndrome.
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Table 2. Phenotypic Data for Affected Family Members in FAF 1 to 4
Pedigree
Number
Age at
Evaluation
(yrs)
Age at
Onset (yrs) Rhythm Treatment
Electrocardiogram Echocardiogram
Comment
HR
(beats/min)
PR
Interval
(ms)
QRS
Interval
(ms)
QTc
(ms)
LA
Size
(mm)
LVSD
(mm)
LVDD
(mm)
EF
(%)
FAF-1
2.2 77 42 PAF BB, AC 63 194 110 460 38 (48) 24 (35) 48 (59) 78
3.2 52 41 PAF — 74 130 100 420 37 (42) 28 (34) 53 (58) 72
4.2 31 31 CAF BB, DZ 95 — 90 410 51 (42) 44 (35) 61 (59) 53 2°CM
32 62 148 100 400 NA NA NA 65
FAF-2
2.2 deceased 50s CAF BB, AC NA NA NA NA NA NA NA NA CVA
2.5 71 58 CAF BB, AC 87 — 100 410 55 (50) 32 (36) 52 (55) 66
3.2 47 36 PAF PPM, AC 70 186 Paced Paced 33 (45) 34 (42) 51 (54) 60
3.3 42 42 PAF BB, AC 98 — 80 400 41 (46) 34 (37) 56 (55) 55 2°CM
45 60 180 85 410 42 (46) 34 (37) 53 (55) 60
FAF-3
2.4 deceased 45 PAF BB, AC NA NA NA NA NA NA NA NA
2.5 80 55 CAF AC 68 — 96 460 50 (52) NA 42 (48) 65
2.6 74 60s CAF Dig, AC 73 — 80 400 48 (45) 34 (32) 47 (49) 55 CVA
2.7 77 45 CAF Dig, AC 87 — 84 360 51 (44) NA NA 81
2.9 73 30 CAF Dig, AC 63 — 110 380 NA NA NA 59
2.12 69 60 PAF BB, FL 46 200 80 420 40 (43) 27 (33) 47 (50) 65 CVA
2.14 63 55 PAF Sot, AC, RFA 66 200 90 410 58 (46) 29 (36) 48 (55) 67
3.8 38 27 CAF BB, Dig 80 — 85 415 NA NA NA NA
FAF-4
2.2 61 58 PAF AC 70 160 80 420 44 (41) 41 (33) 56 (49) 50
72 AJR AC 64 — 115 520 51 (44) 34 (32) 61 (49) 50
2.4 62 42 PAF AC 60 — 110 440 NA NA NA NA
67 JR AC 45 — 110 470 39 (43) 28 (39) 49 (49) 65
2.5 56 36 PAF AC 80 — 100 470 46 (46) 34 (36) 61 (55) 50
66 JR AC 45 — 140 500 51 (50) 40 (36) 66 (55) 50 RBBB, LAFB
3.1 47 43 PAF FL, AC 64 160 120 430 NA NA NA 60
RFA
3.3 38 37 PAF PP, AC 110 160 115 450 41 (42) 32 (37) 54 (53) 55
41 AJR PP, AC 66 — 120 460 41 (43) 39 (34) 54 (53) 50
3.6 45 30 PAF Dig, AC 65 175 90 430 NA NA NA NA
3.8 41 32 PAF, JR AC, PPM 40 — 115 460 47 (46) 40 (39) 64 (56) 55
3.10 29 28 PAF AC 77 145 84 410 40 (45) 36 (40) 56 (57) 50
41 CAF AC 65 — 440 440 48 (46) 39 (40) 56 (57) 50
3.12 36 34 PAF PP, AC 73 162 85 480 46 (43) 38 (37) 54 (53) 55
3.13 34 34 PAF FL, AC 54 115 80 440 42 (43) 30 (35) 46 (53) 60
Values in parenthesis indicate upper limits of normal for age and body surface area (9). Bold font indicates abnormal values. Heart rates (HR) were measured on drug therapy.
AJR  accelerated junctional rhythm; AC  anticoagulation; BB  beta-blockers; Dig  digoxin; DZ  diltiazem; FAF  family with autosomal dominant atrial fibrillation; FL  flecainide; JR  junctional rhythm; LAFB  left
anterior fascicular block; LVDD  left ventricular diastolic dimension; LVSD  left ventricular systolic dimension; PP  propafenone; Sot  sotalol; other abbreviations as in Table 1.
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Figure 1. Haplotype analyses of three pedigrees with familial atrial fibrillation (AF). Pedigree symbols represent the following traits: circles  females;
squares  males; diagonal lines  deceased; filled  AF; hatched  uncertain; empty  asymptomatic and no documented AF. Haplotypes are
comprised of genotypes for eight tightly linked markers spaced 1 to 3 centiMorgans (cM) apart. D10S1694 and D10S1786 define the centromeric and
telomeric boundaries, respectively, of a previously reported familial AF locus on chromosome 10q22-q24. Double recombination events between adjacent
markers were assumed not to have occurred, and haplotypes of deceased individuals were inferred when possible. The patriarchal or matriarchal haplotype
inherited by the majority of individuals with AF within each family is boxed, illustrating at least one affected individual who does not inherit this haplotype.
These data exclude a disease gene for familial AF at this locus. FAF  multi-generation families with autosomal dominant atrial fibrillation.
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Figure 2. Haplotype analyses of a pedigree with familial atrial fibrillation (AF) and early features of dilated cardiomyopathy. Haplotypes were constructed
at a locus for familial AF (a) and loci for familial dilated cardiomyopathy, sinus node dysfunction, conduction system disease, and AF on chromosomes
3p22-p25 (b) and 1q21 (c), where the lamin A/C gene is located. The affected individuals do not inherit the same haplotype, excluding a disease gene at
these loci. FAF  multi-generation families with autosomal dominant atrial fibrillation. Continued on next page
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patients with AF; 15% of patients with lone AF) were
identified with lone AF (mean age at onset 41  9 years,
range 25 to 55 years) and a positive family history (one to
nine additional relatives affected). Phenotypic and family
history data for 46 of the probands are shown in Table 1.
Among the 50 cases of familial AF, four multi-generation
families were identified in which AF appeared to segregate
as an autosomal dominant trait (FAF-1 to -4; Table 2).
Phenotypic data and DNA samples were ascertained from a
sufficient number of relatives to enable testing for linkage at
the chromosome 10q22-q24 locus. The mean age at onset
of AF in FAF-1 to -4 was 38  6, 51  10, 43  13, and
37  9 years, respectively. The disease phenotype in FAF-1
to -3 was similar; the majority of affected family members
presented with symptomatic paroxysmal AF associated with
rapid ventricular response. Two had tachycardia-induced
cardiomyopathy (FAF-1: 4.2; FAF-2: 3.3), which improved
with rate control or maintenance of sinus rhythm (serial
echocardiographic data shown in Table 2). Also notable,
stroke occurred at young ages in these families. An individ-
ual in FAF-2 (2.2) had a stroke at the age of 52 years. In
FAF-3, two individuals (2.6 and 2.12) had strokes at 48 and
52 years of age, respectively.
The disease phenotype in FAF-4 was different from that
in FAF-1 to -3 (Table 2). Asymptomatic AF was more
common (2.5, 3.6, 3.10, and 3.13 were all asymptomatic),
and AF was first diagnosed in two relatives (3.10 and 3.13)
during family screening for the current study. Atrial fibril-
lation in FAF-4 was typically associated with a slow
ventricular response and, consequently, most individuals did
not require rate control therapy. With disease progression,
junctional rhythm with no retrograde atrial conduction
developed in 4 of 10 individuals, including 1 who initially
presented with AF and a rapid ventricular response (3.3). In
one individual (3.8), serial electrophysiologic studies sug-
gested an atrial myopathy, with fractionated atrial electro-
grams progressing to an electrically silent right atrium. He
ultimately required implantation of a permanent pacemaker
for symptomatic junctional bradycardia. Left ventricular
enlargement with low-normal ejection fraction developed in
5 of 10 individuals. Lack of a rapid ventricular response
during AF suggests that the cardiomyopathy in these
individuals is not tachycardia-induced. In summary, AF,
atrial conduction disease, and cardiomyopathy characterize
the phenotype in FAF-4.
Molecular genetic studies. In FAF-1 to -4, phenotypic
characterization and DNA sample collection were sufficient
to test for linkage to the previously reported AF locus on
chromosome 10. In each family, genotypes were scored and
haplotypes were constructed to determine if there was
co-segregation of this locus with AF. The results of haplo-
type analyses are shown in Figures 1 and 2a. These data
revealed lack of a shared haplotype among all affected
individuals within each family, excluding linkage of AF to
the chromosome 10 locus. Thus, at least one additional gene
for familial AF exists. Similarly, in the family with a unique
phenotype (FAF-4), linkage was excluded at two loci
associated with AF and cardiomyopathy (Figs. 2b and 2c).
DISCUSSION
Atrial fibrillation is not generally regarded as a heritable
disorder, and only a few families with this condition have
been described in the literature (6,8,13). The identification
of a genetic locus for autosomal dominant AF established
that, in some cases, AF is a single gene disorder (8).
Although a recent report suggests that familial AF may be
more common than previously recognized (7), there is no
documentation of the overall prevalence of familial AF.
In our clinical practice, we found that at least 5% of all
patients with AF and 15% with lone AF had a positive
family history. Referral bias likely resulted in a dispropor-
tionate number of patients with lone AF evaluated in our
subspecialty Arrhythmia Clinic (36% vs. 2% to 11% in
population studies) (4,5), and our findings may not reflect
the true prevalence of familial disease in patients with AF.
Moreover, the frequency of familial AF could have been
overestimated because a diagnosis of lone AF was not
confirmed in 2 relatives in the “possible” and “probable”
subclassifications of familial disease and some may have had
Figure 2 Continued.
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a non-inherited form of AF secondary to underlying struc-
tural heart disease. Mitigating this possibility, however, is
the relatively young age at onset for AF among the 50
probands and their relatives classified with familial disease,
similar to age at onset for lone AF reported in population-
based studies (4) and suggesting a unique substrate for AF
that differs from those with more common, acquired AF
developing later in life. Alternatively, we may have under-
estimated the true frequency of familial AF. A standardized
initial approach to elicit family history was not applied in
this study, and even a detailed family history may not be a
sensitive marker for inherited cardiovascular diseases (14).
Moreover, systematic clinical screening for occult disease in
first-degree relatives was performed in only 4 of the 50
families. Indeed, lone AF develops as a paroxysmal disorder
that may be clinically silent and/or difficult to document in
individuals with symptomatic disease (15). Determining the
true prevalence of familial AF in patients with AF would
require prospective, longitudinal epidemiologic studies.
In four families with autosomal dominant AF, we have
excluded linkage to the previously identified AF locus on
chromosome 10q22-q24. In one family with AF and car-
diomyopathy, linkage was also excluded to the chromosome
3p22-p25 and lamin A/C loci, which have been associated
with familial AF, sinus node dysfunction, conduction sys-
tem disease, and dilated cardiomyopathy (10,11). These
data indicate that familial AF is genetically heterogeneous
and that at least two disease genes are responsible for this
disorder. Similar to familial cardiomyopathies, the genetic
substrate for familial AF may be quite diverse. This would
be consistent with proposed mechanisms for AF, ranging
from a purely electrical disease to an interaction with an
abnormal morphologic substrate (16–18).
Our findings suggest that familial AF is not uncommon,
family history is an important component of a complete
medical evaluation, and lone AF should raise suspicion of an
inherited form of disease. Because AF is associated with
significant morbidity and mortality, recognition of familial
disease and early identification of affected family members
will allow the initiation of therapies that may prevent or
attenuate some of these complications. Furthermore, iden-
tification of large multi-generation families with AF will
facilitate identification of additional genetic loci for AF.
The ultimate discovery of AF genes will clarify molecular
mechanisms responsible for familial forms of the disease and
may also provide insight into the pathogenesis of more
common, acquired forms of AF. These insights may lead to
improved risk assessment and therapeutic strategies.
Reprint requests and correspondence: Dr. Timothy M. Olson,
Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
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